Logo Image

Immuno-Oncology

Latest News

April 27th 2015
Amgen's T-Vec Receives Poor FDA Staff Review

The accelerated review, the results of which were made public 2 days prior to a vote by an FDA advisory panel on using T-Vec in melaonma, cited concerns over the design and results of a key study with the viral drug.

April 23rd 2015

Genentech's Immuno-Oncology Agent Promising in Advanced Breast Cancer

April 1st 2015

Merck to Test Keytruda With an HDAC Inhibitor

March 25th 2015

Nivolumab Effective in Peviously Treated RCC Patients

March 25th 2015

Melanoma Trial Halted Early; Keytruda Betters Yervoy

Pharma Giants to Collaborate on Immuno-oncology Regimens

By

Merck and Eli Lilly have entered an agreement to collaborate on clinical trials to evaluate the former's recently approved PD-1 inhibitor, Keytruda (pembrolizumab) in combination with Lilly's oncology agents in several clinical trials targeting multiple tumor types.